source
- Arrowhead faces challenges as Ionis's Tryngolza sales fall short, putting sHTG launch at riskIonis Pharmaceuticals reported flat sales of its severe hypertriglyceridemia drug Tryngolza, generating only $9 million and cutting its annual revenue outlook to $50 million. The weak performance…
- Charles River acquires two Frontage bioanalysis labs in Pennsylvania for $470 millionCharles River Laboratories announced it has purchased two laboratory sites from Tigermed’s Frontage in Exton, Pennsylvania, paying $470 million upfront. The labs together span about 150,000 square…